No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CYTK241220C55000
- 0.35
- -0.11-23.91%
15min DelayClose Dec 20 16:00 ET
0.35High0.05Low
0.10Open0.46Pre Close15 Volume1.46K Open Interest55.00Strike Price243.00Turnover8593.33%IV13.26%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.1412Delta0.0441Gamma139.63Leverage Ratio-1059.1566Theta0.0000Rho19.72Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
Why Cytokinetics Stock Was a Nearly 5% Winner Today
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China